



Correction to: Preclinical development of ZED8, an ^{89}Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

Annie Ogasawara¹ · James R. Kiefer² · Herman Gill¹ · Eugene Chiang³ · Shravan Sriraman¹ · Gregory Z. Ferl⁴ · James Ziai⁵ · Sandra Sanabria Bohorquez⁶ · Sebastian Guelman⁷ · Xiangdan Wang⁷ · Jihong Yang⁷ · Minh Michael Phan⁷ · Van Nguyen⁷ · Shan Chung⁷ · Christine Yu² · Jeff Tinianow¹ · Stijn Jan Hein Waaijer¹ · Alex De Crespigny⁶ · Jan Marik¹ · C. Andrew Boswell⁴ · Tanja Zabka⁸ · Karin Staflin⁹ · Simon-Peter Williams¹

Published online: 25 November 2022

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Correction to: European Journal of Nuclear Medicine and Molecular Imaging

<https://doi.org/10.1007/s00259-022-05968-6>

The authors regret that the text captured in bold font style below that appears in the original article should have been deleted.

“Preliminary results from the first clinical assessments of ZED8 have been presented [25], with further evaluation in multiple solid tumor indications underway (**Nature**

Medicine manuscript NMEDA119285A provisionally accepted pending final revision)”.

The original article can be found at <https://doi.org/10.1007/s00259-022-05968-6>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Erratum

The original article can be found online at <https://doi.org/10.1007/s00259-022-05968-6>.

✉ Simon-Peter Williams
williams.simon@gene.com

¹ Department of Biomedical Imaging, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

² Department of Structural Biology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

³ Department of Cancer Immunology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

⁴ Preclinical and Translational Pharmacokinetics, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

⁵ Research Pathology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

⁶ Oncology Exploratory Clinical Development, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

⁷ BioAnalytical Sciences, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

⁸ Safety Assessment Pathology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA

⁹ Safety Assessment Toxicology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA